| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1345/APH.1L180 |
| P698 | PubMed publication ID | 18957628 |
| P2093 | author name string | Matthew T Harris | |
| Judy K Wu | |||
| P2860 | cites work | Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients | Q28265266 |
| Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation | Q33376066 | ||
| Experiences with leflunomide in solid organ transplantation | Q34555437 | ||
| Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation | Q34719108 | ||
| Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations | Q36136619 | ||
| BK virus: opportunity makes a pathogen | Q36188861 | ||
| BK virus nephritis after renal transplantation | Q36361588 | ||
| Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients | Q36492408 | ||
| Polyomavirus-associated nephropathy: update on antiviral strategies | Q36492418 | ||
| Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients | Q36662024 | ||
| BK virus nephropathy and kidney transplantation | Q36910661 | ||
| Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients | Q44104230 | ||
| Polyomavirus BK infection in Greek renal transplant recipients | Q44249083 | ||
| Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system | Q45267785 | ||
| Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome | Q45407573 | ||
| Prevalence and clinical course of BK virus nephropathy in pancreas after kidney transplant patients | Q45409056 | ||
| Therapeutic options in BK virus-associated interstitial nephritis | Q45415648 | ||
| Treatment of renal allograft polyoma BK virus infection with leflunomide | Q45418931 | ||
| Leflunomide for polyomavirus type BK nephropathy | Q46398377 | ||
| A case of polyomavirus-associated nephropathy presenting late after transplantation | Q46707090 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1679-1685 | |
| P577 | publication date | 2008-10-28 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Use of leflunomide in the treatment of polyomavirus BK-associated nephropathy | |
| P478 | volume | 42 |
| Q39587782 | Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. |
| Q39180715 | BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies. |
| Q39191858 | BK Virus Encephalitis in HIV-Infected Patients: Case Report and Review. |
| Q38164695 | BK virus encephalitis: case report, review of the literature, and description of a novel treatment modality |
| Q37616854 | BK virus nephropathy: a pediatric nephrologist's perspective |
| Q24627138 | Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation |
| Q59353646 | Fluoroquinolones and BK Virus Nephropathy: A Myth or a Reality |
| Q92477903 | Human BK and JC polyomaviruses: Molecular insights and prevalence in Asia |
| Q40315102 | Immunosuppressive effects and mechanisms of leflunomide in dengue virus infection of human dendritic cells |
| Q35930371 | Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia |
| Q37813410 | Infection and chronic allograft dysfunction |
| Q43287356 | Oscillation between BK virus nephropathy and rejection--the frustrating course of a living donor transplantation |
| Q37889145 | Polyoma BK virus: an emerging opportunistic infectious agent of the human central nervous system |
| Q37821326 | The BK virus in renal transplant recipients-review of pathogenesis, diagnosis, and treatment |
Search more.